Dashboard
Poor Management Efficiency with a low ROE of 4.41%
- The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.41%
With a fall in Operating Profit of -1866.07%, the company declared Very Negative results in Jun 25
Risky - Negative Operating Profits
Stock DNA
Pharmaceuticals & Biotechnology
JPY 12,579 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.10
-9.32%
2.00
Total Returns (Price + Dividend) 
RaQualia Pharma, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

RaQualia Pharma Hits Day Low of JPY 556 Amid Price Pressure
RaQualia Pharma, Inc. faced a notable stock decline today, reaching an intraday low amid ongoing operational challenges. Despite a strong year-to-date performance, the company struggles with negative operating profit, low return on equity, rising raw material costs, and declining net sales, impacting its long-term outlook.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is -25.17% vs 18.47% in Jun 2024
YoY Growth in quarter ended Jun 2025 is -42.19% vs -241.35% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 63.45% vs -34.85% in Dec 2023
YoY Growth in year ended Dec 2024 is -52.92% vs -144.75% in Dec 2023






